Jefferies reiterates Buy on Wave Life Sciences stock ahead of May data

Jefferies reiterated a Buy with a $28 price target on Wave Life Sciences versus the current share price of $12.20 (implying ~130% upside); Mizuho also raised its target to $27 from $22. The stock is +75% over six months but -32% YTD; Wave beat Q4/FY2025 revenue estimates but missed on EPS and faces financial pressure after a major collaboration ended, though InvestingPro notes cash exceeds debt. Key near-term catalysts include imminent updates from 240mg (6‑month) and 400mg (3‑month) cohorts, May readouts for 400mg multi-dose and 600mg single-dose, and potential regulatory pivotal discussions in 2026.

Analysis

A positive clinical readout for a durable, repeat-dosed RNA editor would change partner economics across rare-disease platforms: pharma buyers would favor optionality (light-touch licensing with milestone/royalty structures) over owning full in-house editing platforms, compressing upfront M&A valuations but increasing contingent milestone pools. That dynamic favors asset-light companies with near-term binary catalysts and deep-pocketed collaborators willing to pay for de-risked pivotal programs, while penalizing vertically integrated developers who carry high fixed R&D and manufacturing costs.

Key risks are binary safety/durability outcomes and the financing gap between early-stage signal and a registrational study; a move from signal to pivotal commonly requires high-commitment capital (order of magnitude: low hundreds of millions), which can create meaningful dilution or force suboptimal partnering terms within 6–24 months. A surprise safety signal or a durability profile that mandates higher, more frequent dosing would cascade into bigger manufacturing needs and slower payer uptake, materially compressing valuation multiples used by potential acquirers.

Second-order supply-chain effects: if repeat dosing becomes standard, demand shifts from single-use gene therapy CMOs toward scalable RNA/drug-product CMOs and fill-finish capacity, tightening that part of the market and lifting margins for specialist CDMOs. Strategically, success would also refocus IP races toward off-target biochemistry and delivery orchestration rather than nuclease engineering, altering long-term winners among editing-platform players.

Key Decisions for Investors

• Long WVE (1–2% portfolio): accumulate into weakness ahead of the next clinical readout window with a 6–12 month horizon. Risk: stop-loss at -40% from entry; Reward: target a 100% upside if results materially de-risk a pivotal path and trigger partnership interest.
• Buy WVE 18-month LEAP calls (~35% OTM) sized at 0.5–1% portfolio to cap downside to premium while capturing asymmetric upside from regulatory/pivotal discussions within 12–24 months. Risk: total premium loss; Reward: >2x payoff if program advances to a funded pivotal or attracts a licensing/acquisition offer.
• Paired trade (market-neutral hedge): long WVE / short BEAM (smaller notional on BEAM) over 6–18 months to express a bet that validation of non-permanent RNA editing shifts relative value toward platform-agnostic, asset-light assets. Risk: BEAM could rerate independently; Reward: hedge reduces binary-single-stock risk while retaining upside to WVE-specific data.
• Protective hedge for existing longs: buy 6–9 month WVE puts ~25% OTM as tail insurance during the next readout cycle. Risk: premium paid; Reward: limits downside from an adverse safety/durability surprise that would likely cause >30% gap down.